Kornimate/medical-research-clean huggingface dataset:
neuronal correlates of altered states of consciousness

Conditions: Healthy

Summary: the aim of the present study is to assess the neuronal correlates of alterations in waking consciousness pharmacologically induced by a 5-hydroxytryptamine (ht)2a receptor agonist in healthy subjects using functional magnetic resonance imaging (fmri).

functional neuroimaging may be useful in the diagnosis and characterization of early schizophrenia. however, little is known about how the subjectively experienced alterations in consciousness and perception are related with objective neuroimaging measures. the present study explores the association of subjective alterations and objective imaging findings and will inform us on the neuronal correlates of psychotic states and whether subjective alterations in perception translate into neuronal activation patterns that can be objectively measured in a brain scanner. therefore, alterations in consciousness will be assessed in 20 healthy subjects using a random order 2-period (normal and altered state of consciousness) cross-over design. alterations in consciousness will be induced by the hallucinogenic 5-hydroxytryptamine (ht)2a receptor agonist (5-ht2a) receptor agonist lysergic acid diethylamide (lsd).

Eligibility criteria:
inclusion criteria: 1. age between 25 and 65 years 2. understanding of the german language 3. understanding the procedures and the risks associated with the study 4. participants must be willing to adhere to the protocol and sign the consent form 5. participants must be willing to refrain from taking illicit psychoactive substances during the study. 6. participants must be willing to drink only alcohol-free liquids and no xanthine-containing liquids (such as coffee, black or green tea, red bull, chocolate) after midnight of the evening before the study session, as well as during the study day. 7. women of childbearing potential must have a negative pregnancy test at the beginning of the study and before each study session. exclusion criteria: 1. chronic or acute medical condition 2. current or previous major psychiatric disorder 3. psychotic disorder in first-degree relatives 4. illicit substance use (except tetrahydrocannabinol (thc)-containing products) more than 10 times or any time within the previous month. 5. pregnant or nursing women. 6. participation in another clinical trial (currently or within the last 30 days)

Keywords: altered state of consciousness functional magnetic resonance imaging (fmri) hallucination model psychosis serotonin receptor lsd
ablation of complex fractionated electrograms with or without additional linear lesions for persistent atrial fibrillation

Conditions: Atrial Fibrillation; Recurrence

Summary: while there is a consensus to perform pulmonary vein isolation (pvi) as a cornerstone for paroxysmal and persistent atrial fibrillation (af), different additional ablation approaches are used for substrate modification: linear lesions, ablation of complex fractionated atrial electrograms (cfae) or a combination of both. the aim of this study is to determine whether there is a difference in terms of freedom from arrhythmia recurrence between pvi with cfae ablation in combination or not with linear lesions in patients with persistent af.


Eligibility criteria:
inclusion criteria: * patients with symptomatic persistent af * after pvi +cfae ablation, no termination into sinusrhythm or atrial tachycardia exclusion criteria: * left atrial thrombus

Keywords: atrial fibrillation recurrence cfae linear ablation
screening of fibrosing and/or viral chronic hepatopathies in jail

Conditions: Liver Fibrosis

Summary: the prevalence of chronic hepatopathies is high in jail. however, the medical care of these hepatopathies is few developed. this study is an observational, an epidemiologic (screening and prevalence of fibrosing hepatopathies) and an evaluating study for a better taking care of these hepatopathies in jail. the aims of the study will be to evaluate the diagnostic performance of the fibrometer score in the screening of the hepatic fibrosis in persons with multiple risk factors for liver fibrosis (alcoholism, intravenous drug users, tattoo, and virological status) with fibroscan® as gold standard; to evaluate the feasibility of these different screening tools for chronic hepatopathies in jail and to evaluate the prevalence of the fibrosing hepatopathies with clinically significant fibrosis and theirs risk factors, alcohol and hepatitis b and hepatitis c viruses in population from angers jail.

primary outcome: screening of clinically significant fibrosis with fibrometer blood score. screening for hepatitis b and hepatitis c viruses. secondary outcome: clinically significant fibrosis confirmed with fibroscan®. the means for this study are a clinical questionnaire, a virological screening, a blood score for liver fibrosis: fibrometer according to cause of the fibrosis and fibroscan® is referent and independent examination. the expected results from this study are the knowledge of the prevalence of hepatopathies with hepatic fibrosis will be able to justify, possibly, a screening politic of them. this study will permit to evaluate the feasibility of noninvasive screening of the liver fibrosis in the goal to suppress the liver biopsy in a population having numerous drawbacks.

Eligibility criteria:
inclusion criteria: * person over 18, * all new inmates, for less than one month, in angers jail, * to have a written informed consent. exclusion criteria: * no consent obtained from person, * detention inferior to one month, * person under 18.

Keywords: liver fibrosis hepatitis b virus and c virus fibrometer fibroscan®
treatment of restless leg syndrome (rls) augmentation with ecopipam, a d1 specific antagonist

Conditions: Restless Legs Syndrome; Augmentation

Summary: this is an exploratory, double blinded cross-over study of the d1 antagonist ecopipam treat patients currently having dopamine agonist induced augmentation in restless legs syndrome. each arm is 6 weeks composed of an unforced titration up to 100mg/day separated by a 2-week wash-out period. efficacy points will include the irls, augmentation scales, sleep scales, clinical impressions and fatigue/mood scales.

this is a double-blind, exploratory proof of concept, cross-over trial of the d1 antagonist ecopipam for subjects with augmented restless legs syndrome (rls). investigators will recruit 10 subjects taking dopamine agonists for rls who are currently experiencing augmentation. the goal is to have 8 completers. there is no power analysis as this is an exploratory study and there is no previous data on treatment of augmentation. "meaningful improvement" is not even established. a safety analysis will be done after 5 subjects have been enrolled. duration of study and is based mostly on contracted drug availability for this pilot study.

Eligibility criteria:
inclusion criteria: * provide consent to participate in the study * individuals of either sex, 21-80 years of age * clinically defined restless leg syndrome, and problematic augmentation currently on monotherapy with dopaminergic treatment. exclusion criteria: * current use of opioid medications * clinical relevant depression or other medical problems that in the opinion of the investigator would not allow for safe completion of the protocol. * suicidal ideation * history of epilepsy * current mao inhibitors
comparison of two different treatment methods

Conditions: Subacromial Impingement Syndrome; Musculoskeletal Diseases; Musculoskeletal Injury; Musculoskeletal Pain; Weakness, Muscle

Summary: a number of previous studies investigated the effects of kinesiotaping (kt) in subacromial impingement syndrome (sis).

subacromial impingement syndrome (sis) is characterized by shoulder pain that is exacerbated with especially arm elevation or overhead physical activities.

Eligibility criteria:
inclusion criteria: * impingement symptoms in clinical tests * pain \>1 month exclusion criteria: * any shoulder pathology. * have chronic systemic diseases or infections. * history of any surgery shoulder complex. * steroid injections and therapeutic approaches

Keywords: subacromial impingement syndrome mulligan mobilization technique kinesiotaping physiotherapy
method development and assessment of the effects of tobacco products on oral cavity cells

Conditions: Squamous Cell Carcinoma

Summary: collection of tissues for analysis from patients undergoing elective neck dissection. the hypothesis of the study is that specific genetic alterations occur in head and neck cancers that have spread to regional and/or distant sites, and these alterations can be identified from biopsy specimens to allow more accurate staging of tumor and better treatment planning.

the standard of care for the treatment of most squamous cell carcinoma of the head and neck is surgical extirpation of the primary tumor and elective neck dissection to remove regional nodes at risk for spread. via this treatment regimen, the investigators will be able to prospectively obtain tissues for analysis from patients undergoing elective neck dissection. the specific aims of this study are to compare gene expression between head and neck tumors with and without regional lymph node metastases, and to compare gene expression between head and neck tumor with and without distant metastases.

Eligibility criteria:
inclusion criteria: * all patients with biochemical evidence of squamous cell carcinoma of the head and neck. exclusion criteria: * patients without biomedical evidence of squamous cell carcinoma.
mixed strain h. pylori infection in patients who have problems with eradication of h. pylori

Conditions: H. Pylori Eradication Failure

Summary: the purpose of this study is to determine whether mixed h. pylori strain infection is the reason for eradication failure during treatment of h. pylori infection. the investigators present the results got from extensive sampling of biopsy samples taken from individuals diagnosed with h. pylori connected disease. the investigators were looking for individuals that were not able to eradicate h. pylori although they had susceptibility testing tailored antibiotic therapy. on their control visit after 2 months they presented again with h. pylori although at their first visit they had h. pylori isolated from biopsy sample sensitive to all antibiotics prescribed. multi locus sequence typing (mlst) was used to prove the sequence type of h. pylori and e test was used to determine susceptibility of h. pylori to antibiotics.


Eligibility criteria:
inclusion criteria: * people who have h. pylori sensitive to all antibiotics before therapy and and do not eradicate h. pylori after appropriate antibiotic therapy. exclusion criteria: * people who did not eradicate h. pylori because of primary resistance to antibiotics.
detecting chemosensitivity and predicting treatmemt efficacy with ctcs in mnpc

Conditions: Circulating Tumor Cell; Nasopharyngeal Carcinoma; Distant Metastases.Clinical; Effects of Chemotherapy

Summary: the prospective observational clinical study will recruit 50 metastatic nasopharyngeal carcinoma (mnpc) patients, detecting patient's chemosensitivity with the circulating tumor cells (ctcs) from peripheral blood and prdicting patient's treatment efficacy with ctcs dynamic change.


Eligibility criteria:
inclusion criteria: * npc patients with distant metastasis after 3 months of primary radiotherapy, and not suitable for local treatment * at least having one measurable metastatic lesion * all genders，range from 18～70 years old * ecog score 0 \~ 1 * expected survival time ≥ 3 months * white blood cell(wbc) count ≥ 3×109/l, neutrophile granulocyte(ne) count ≥ 1.5×109/l, hemoglobin(hgb) ≥ 90g/l, platelet(plt) count ≥ 100×109/l * alanine aminotransferase (alt) or aspartate aminotransferase(ast) \< 2.5×upper limit of normal(uln), bilirubin(bun) or creatinine(cre) \< 1.5×uln, alanine aminotransferase (ccr) ≥ 60ml/min * inform consent form exclusion criteria: * have or are suffering from other malignant tumors; * participating in other clinical trials; * drug or alcohol addition; * do not have full capacity for civil acts; * mental disorder; * pregnancy or lactation; * severe complication, eg, uncontrolled hypertension.
incidence of perioperative cerebrovascular stroke in assuit university hospitals , hospital based study

Conditions: Perioperative Complication

Summary: stroke is the most common cause of disability in elderly people (over 65years of age) and the third most common cause of death in the world . the world health organization estimates that one in six people globally will suffer from stroke in their lifetime. perioperative stroke is the most unwanted complication for patients, as well as for surgeons and anesthesiologists . the reported risk of perioperative stroke varies with the type of surgery. its incidence is generally not high (approximate 0.1-1.9%) in non-cardiac, non-neurologic, and non-major surgery however, it may occur in up to 10% of patients undergoing high-risk cardiac or brain surgery . patients with perioperative stroke are less likely to have a good functional outcome and have an eight-fold higher mortality compared with those without perioperative stroke


Eligibility criteria:
inclusion criteria: 1. all patients admitted to general surgery, cardiothorasic surgery and vascular surgery depatments in assuit university hospitals during one year that will going to operation 2. all age groups . 3. both sex. exclusion criteria: * other surgical departments * patients with syptoms that related to delayed recovery from anaesthesia .
impact of swab site and sample collector on testing sensitivity for covid-19 virus in symptomatic individuals

Conditions: Infections, Respiratory; Fever; Cough

Summary: operational project to compare clinician collected nasopharyngeal (np) samples to patient-obtained tongue, nasal and mid-turbinate (mt) samples in the detection of sars-cov-2 in an outpatient clinic setting

this work will serve both the everett clinic and broader unitedhealth group patient populations as well as advance the public health emergency (phe) response to the community spread of sars-cov-2 virus, especially as the number of cases and deaths continues to rise in many geographies. leveraging our presence in the seattle/puget sound area with everett clinic, we intend to develop a model that can screen a large number of patients at varying levels of risk and manifestation of clinical symptoms while conserving personal protective equipment (ppe) and decreasing transmission risk to health care workers. this will also serve to support the enterprise and public health response. towards this goal, we must first assess the equivalence between clinician-collected nasopharyngeal (np) samples to patient-collected tongue, nasal, and mid-turbinate (mt) samples to detect sars-cov-2 across a broad cross-section of the population.

Eligibility criteria:
inclusion criteria: * able to consent and agree to participate in the project after discussing the project * coming to the everett clinic during the operational project duration * evidence of upper respiratory symptoms suggesting higher risk of testing positive for sars-cov-2 virus. exclusion criteria: * not able to demonstrate understanding of the study * not willing to commit to having all four samples collected * medical history evidencing any of the following * active nosebleed in the past 24 hours * nasal surgery in the past two weeks * chemotherapy treatment with low platelet and low white blood cell counts * acute facial trauma
rotavirus vaccine produced by butantan institute

Conditions: Rotavirus Infections

Summary: the purpose of this study is to describe the safety, tolerability and immunogenicity of the pentavalent rotavirus vaccine produced by butantan institute.

the brazilian national immunization program (pni) has introduced a oral monovalent vaccine against rotavirus for infants in its immunization schedule since 2006. its introduction increased the brazilian ministry of health budget because the vaccination in brazil is free of charge. an agreement between path foundation and butantan institute has made possible the transfer of technology to butantan institute to produce, at a reduced cost, a pentavalent rotavirus vaccine including the the rotavirus serotypes more frequent in brazil.

Eligibility criteria:
inclusion criteria: * male healthy * age ≥18-40 years * not taking immunosuppressive drugs * no clinical history of gastrointestinal diseases or surgeries * no history of cardiac, neurologic, immunologic or endocrine diseases * normal eligibility laboratory tests * to be willing to participate and sign the informed consent form * no participation in another clinical trial in the past 6 months exclusion criteria: * had received any other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrollment in this study

Keywords: brazilian pentavalent rotavirus vaccine safety tolerability immunogenicity
evaluating the effectiveness of an individualized nutrition and physical activity counseling program

Conditions: Breast Cancer

Summary: more than 65% of breast cancer survivors are overweight and less than one-third participate in recommended levels of physical exercise. obese breast cancer survivors have been found to have greater than a two-fold increase in mortality compared to women with normal body mass index (bmi). the current standard for weight loss interventions involves in-person counseling. however, this incurs costs related to travel for counseling sessions, potentially limiting program participation, compliance and sustainability.this is a pilot study of an individualized in-person and telephone-based nutrition and exercise counseling program.


Eligibility criteria:
inclusion criteria: * breast cancer diagnosis (stage 0-iii) * body mass index of 25mg/k2 or greater * actively being followed by medical oncologist, radiation oncologist, and/or breast surgeon at maroone cancer center * able and willing to participate in nutrition counseling at maroone cancer center * able (cleared by participant's primary oncologist) and willing to perform cardiopulmonary exercise testing * participants must have the ability to understand and the willingness to sign a written informed consent document * performance status 0 or 1 as per ecog scale \[see appendix iv\] exclusion criteria: * body mass index below 25kg/m2 * no prior history of breast cancer * history of metastatic disease * not being followed by medical oncologist, radiation oncologist, and/or breast surgeon at maroone cancer center * unable or unwilling to participate in nutrition counseling at maroone cancer center * participants with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * participants actively undergoing chemotherapy, immunotherapy or radiation treatment. however, participants currently taking hormonal therapy, such as selective estrogen receptor modulators (serms), or aromatase inhibitors, may be included in the study.
belinostat in relapsed or refractory peripheral t-cell lymphoma

Conditions: Peripheral T-cell Lymphoma

Summary: the purpose of this study is to assess efficacy and safety of belinostat in participants with relapsed or refractory peripheral t-cell lymphoma (ptcl), who failed at least one prior systemic therapy.

this is an open-label, multicenter, single arm efficacy and safety study in participants with relapsed or refractory peripheral t-cell lymphoma, who have failed at least one prior systemic therapy. approximately 120 participants will be enrolled. participants will be treated with 1000 mg/m\^2 belinostat administered as a 30-minute iv infusion on days 1-5 of every 3-week cycle until there is disease progression or unmanageable treatment-related toxicities. the primary study endpoint is objective response rate (orr) based on the international harmonization project (ihp) revision international working group (iwg) criteria. safety will be evaluated during the study and for 30 days after the last administration of study drug. adverse events and laboratory studies will be graded according to national cancer institute - common terminology criteria for adverse events (nci-ctcae) v. 3.0.

Eligibility criteria:
inclusion criteria: * a histologically confirmed diagnosis of ptcl * participants must have relapsed or refractory disease after at least one prior systemic anticancer regimen. systemic anticancer therapy is defined as chemotherapy or immunotherapy administered systemically. * participants must have at least one site of disease measurable in two dimensions by computed tomography (ct). * age ≥ 18 years. * adequate bone marrow, liver, and renal functions. * eastern cooperative oncology group (ecog) performance status 0-2. * negative pregnancy test for women of childbearing potential. exclusion criteria: * relapse within 100 days of autologous or allogeneic bone marrow transplant. * prior histone deacetylase (hdac) inhibitor therapy. * co-existing active infection or any medical condition likely to interfere with trial procedures. * severe cardiovascular disease. * clinically significant central nervous system disorders with altered mental status or psychiatric disorders precluding understanding of the informed consent process and/or completion of the necessary studies. * active concurrent malignancy (except adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix). * symptomatic or untreated central nervous system (cns) metastases. * pregnant or breast-feeding women. * known infection with human immunodeficiency virus (hiv), hepatitis b or hepatitis c.

Keywords: belinostat peripheral t-cell lymphoma pxd101 ptcl hdac inhibitor histone deacetylase inhibitor
a study of peginterferon alfa-2a in combination with ribavirin in patients with chronic hepatitis c

Conditions: Chronic Hepatitis C

Summary: this study evaluated the efficacy and safety of the combination of peginterferon alfa-2a plus ribavirin in treatment-naïve patients with hcv genotype 1b infection, compared with peginterferon alfa-2a monotherapy. additionally, the study evaluated the efficacy and safety of the combination of peginterferon alfa-2a plus ribavirin in patients with chc who had failed to respond to previous conventional-interferon based therapy.

treatment-naïve patients were randomly assigned in a 1:1 ratio to 48 weeks of double-blind treatment with subcutaneous, once-weekly injections of 180 μg of peginterferon alfa-2a (40kd) plus either twice-daily oral ribavirin (600 to 1000mg/day) or placebo. all patients who had received previous treatment with conventional interferon but had failed to respond (no suppression of hcv-rna below detection limits of a sensitive assay) or had relapsed (reversion to hcv-rna positive state after suppression) received the combination of peginterferon alfa-2a (40kd) plus ribavirin for 48 weeks at the dosages stated above.

Eligibility criteria:
inclusion criteria: * adult patients with quantifiable serum hcv-rna (≥500 iu/ml)) * elevated serum alanine aminotransferase activity (≥45 iu per liter)within six months of screening * liver biopsy findings consistent with a diagnosis of chronic hepatitis c. exclusion criteria: * patients with neutropenia (fewer than 1,500 neutrophils per cubic millimeter) * leukopenia (fewer than 3,000 white blood cells per cubic millimeter) * thrombocytopenia (fewer than 90,000 platelets per cubic millimeter) * anemia (less than 12 g hemoglobin per deciliter ) * hepatitis b co-infection * decompensated liver disease * organ transplant * creatinine clearance less than 50 milliliters per minute * poorly controlled psychiatric disease * poorly controlled diabetes * malignant neoplastic disease * severe cardiac or chronic pulmonary disease * immunologically mediated disease * retinopathy.